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Abstract
Background Intraoperative parathyroid hormone (ioPTH) is
used during minimally invasive parathyroidectomy (MIP)
to predict the success of surgery and should be accurate
with a short turnaround time.
Material and method We developed an ioPTH point-of-
care (POC) assay on Philips handheld magnotech system.
Magnotech technology is based on magnetically controlled
movement of superparamagnetic nanoparticles in stationary
sample fluid. During first phase, intact-PTH is captured by
magnetic particles coated with anti-N-terminal-PTH anti-
bodies. Subsequently, magnetic particles are collected by
magnetic forces at sensor surface coated with anti-C-
terminal-PTH antibodies. Unbound/nonspecifically bound
particles are pulled away from detection surface, using a
second magnetic force. Amount of specifically bound
particles is measured using a surface-sensitive optical
imaging technique.
Results ioPTH test could be performed with a turnaround
time of less than 10 min and could detect low intact-PTH
concentrations (picomolar). Integrated cartridge contains a
blood separation filter and dry reagents for the assay.
Conclusion The next magnotech ioPTH assay will be the
only POC test able to give accurate results in less than
10 min, using 25 μL of whole blood. Thanks to the ease-of-
use, magnotech ioPTH could be performed in the operating
theater by any member of surgical staff.
Keywords Intraoperative PTH.Point-of-care test.
Turnaround time.Operating theater.Magnotech.Minimal
invasive parathyroidectomy
Abbreviations
ioPTH Intra-operative PTH
PTH Parathyroid hormone
POC Point-of-care
MIP Minimal invasive parathyroidectomy
PHPT Primary hyperparathyroidism
FTIR Frustrated total internal reflection
RT Room temperature
CV Coefficient of variation
Introduction
Primary hyperparathyroidism (PHPT) is caused by a single-
gland disease in more than 80% of patients, for whom
unilateral cervical exploration would be beneficial com-
pared with a four-gland exploration [1]. The improvement
in imaging with 99mTc-labeled sestamibi scintigraphy and
ultrasonography of the neck to localize a single adenoma
preoperatively, has made minimally invasive parathyroid-
ectomy (MIP) the preferred approach to PHPT for most
endocrine surgeons [2, 3]. Upto 92% of patients with
positive localization studies undergo MIP [4]. MIP is often
coupled with intraoperative parathyroid hormone (ioPTH)
monitoring during surgery to confirm the completeness of
resection of the hyperfunctioning parathyroid gland and to
reveal cases of multiple-gland parathyroid disease not
recognized on imaging [5, 6]. Such approaches can reduce
the costs of medical care by decreasing the duration of the
surgery and lengths of stay, changing from an inpatient to
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DOI 10.1007/s00423-010-0733-zanoutpatient procedure[7]. Patient satisfaction is also greater
with respect to cosmetic result and postoperative pain.
Intact-PTH consists of a single polypeptide chain,
containing 84 amino acids with amino and carboxy
terminals, which is produced only in the parathyroid glands
and secreted into the bloodstream. The circulating (1–84)
PTH molecule has a half-life of only 5 min. Blood
concentrations of intact-PTH rapidly decrease after removal
of hypersecreting parathyroid gland. Typically, PTH con-
centrations are measured at baseline, before exploration,
and then at 5–10 min post-excision, with a 50% decrease in
PTH values from the highest baseline observed if all
hypersecreting tissue has been removed [8]. Since the
mid-1990s, the development of rapid ioPTH assays,
improving the turnaround time of the result, allowed for
its practical use in the surgical management of PHPT [9,
10]. Rapid ioPTH assays have incubation times ranging
from 10 to 30 min, giving turnaround times of up to 1 h.
Most of the laboratories performing rapid PTH testing are
carrying out testing in the central laboratory on an
automated analyzer [11]. An on-site approach, i.e., operat-
ing theater testing requires additional instrument and
operator training and a dedicated laboratory technician.
Royal Philips Electronics has developed a handheld
immunoassay system called magnotech for the point-of-
care (POC) testing that can measure picomolar concen-
trations of analytes in 10 min or less [12–14]. We worked
on the development of an ioPTH assay on the magnotech
system with a turnaround time of less than 10 min [15, 16].
Such an assay would have the potential to be used in the
operating theater. We present here the preliminary results
obtained internally with an in-house magnotech ioPTH
assay.
Materials and methods
Magnotech technology
The diagnostic system is based on Philips' proprietary
magnotech immunoassay technology (http://www.philips.
com/magnotech)[ 13, 14]. The system consists of a
handheld analyzer instrument and a disposable self-
contained cartridge. Magnetic nanoparticles that have been
functionalized with antibodies are used to capture and to
detect the analyte molecules. Magnetic forces are used to
transport the nanoparticles to the sensor surface, which is
also coated with antibodies where they can bind. By
collecting all magnetic particles near the sensor surface, a
significant increase in analyte concentration is achieved,
which speeds up the binding kinetics, shortening the assay
time. All assay reagents are stored inside the cartridge in a
dry form; therefore, once the sample liquid has been added
to the cartridge, no further operator interaction is required.
The short measurement time, in combination with the high
ease-of-use, makes the test very suitable for ioPTH testing
use, enabling the surgical staff to perform the measurement
during the operation without the need for a laboratory
technician. The magnotech system uses the principle of
frustrated total internal reflection (FTIR) to detect the
presence of any magnetic nanoparticles bound to the sensor
surface. The FTIR principle is illustrated in Fig. 1. Light is
projected on the surface of the cartridge at an angle that is
slightly shallower than the critical angle, causing a
reflection that is imaged on a camera sensor. In the absence
of any magnetic particles, the beam of light is reflected at
full intensity, resulting in a bright image. When nano-
particles did bind on the sensor surface, some of the light is
Fig. 1 FTIR detection principle.
The presence of bound magnetic
nanoparticles “frustrates” the total
internal reflection of a light beam,
resulting in a reduction of the
reflected light proportional to the
number of magnetic particles.
(Reprinted with permission of
Philips)
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decreased intensity of the reflected light. This decrease in
signal is proportional to the number of particles bound, and
hence, to the analyte concentration.
Magnotech ioPTH assay
We have developed an immunoassay on magnotech system
for the in vitro quantitative determination of intact PTH in
human blood. Magnotech ioPTH assay uses a sandwich test
principle in which a monoclonal antibody reacts with the N-
terminal fragment (1–34) of PTH, and a second antibody
reacts with the C-terminal fragment (39–84) of PTH. In the
first step of the assay, the PTH molecules are captured on
magnetic nanoparticles coated with anti-N-terminal PTH
antibodies (Fig. 2a). Since the combined surface area of the
magnetic particles is large, this capture phase goes very
quickly. In the next step of the assay, all magnetic particles
are attracted by a magnetic force directed towards the sensor
surface covered with an anti-C terminal PTH antibody
(Fig. 2b). The magnetic particles that captured a PTH
molecule have a chance to bind to the antibodies on the
detection spot in a sandwich assay format. However, many
particles that did not capture any PTH were also attracted,
but these cannot bind. The unbound labels are removed by a
magnetic “washing” step that consists of a magnetic force
directed away from the sensor surface (Fig. 2c). After the
magnetic washing step, only the specifically bound labels
remain at the sensor surface and the unbound beads have
been moved into the bulk of the liquid. The number of
bound labels is finally quantified, using a surface-sensitive
technique based on the FTIR principle. In this assay format,
no other liquids are present besides the sample liquid,
making it a truly homogeneous assay. All assay reagents
are stored inside the cartridge in a dry form, so no additional
sample pretreatment steps are required and the sample can be
added directly to the cartridge.
Functionalization of carboxylated-magnetic nanoparticles
Magnetic nanoparticles were coated with anti-N-terminal
PTH antibodies, using EDC (N-Ethyl-N′-(3-dimethylami-
nopropyl) carbodiimide) chemistry, as described by
Dittmer et.al. [12]. Tracer anti-N-terminal PTH antibody
was added to 10 mg/mL of superparamagnetic particles
functionalized with carboxylic acid groups (500 nm in
diameter) to a final concentration of 20 μg antibody/mg
particles in 50 mM of MES (2-N-morpholinoethanesul-
fonic acid; pH 6.2) and incubated for 30 min on a roller-
mixer at room temperature (RT). Next, the antibodies were
coupled to the carboxyl groups of the particles with 2 mg/mL
EDC (Sigma–Aldrich Corp.) for 30 min on a roller-mixer at
RT. Finally, the reaction was inactivated with 100 mM Tris
(pH 8), and the functionalized particles were transferred to a
storage buffer.
Production of integrated PTH cartridges
The integrated cartridge consisted of three components, e.g.,
fluidic part, optical part, and a double-sided biocompatible
adhesive tape.
The fluidic part is the plastic top part of the cartridge and
was injection-molded in-house (Philips, Eindhoven, The
Netherlands). Functionalized particles (200 nL) were depos-
ited into a cavity in the top plastic part of the cartridge, using
the Nanodrop NS-2Stage (Innovadyne Technologies, Inc.
Carnforth, UK). The particles were dried at 37°C for 1 h, and
subsequently, sealed with silica bags and stored at 4°C.
The optical part is the plastic bottom part of the
integrated cartridge, comprising the detection surface and
Fig. 2 Magnotech assay principle. During the first step of the assay,
the PTH molecules are captured on magnetic nanoparticles (a). Next,
the magnetic particles are attracted towards the sensor surface, where
the labels that captured a target can bind in a sandwich format (b).
Finally, the unbound magnetic particles are removed by a magnetic
force directed away from the sensor surface (c) after which the number
of bound labels is quantified. (Reprinted with permission of Philips)
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microtiter plate substrate material. The detection spot was
functionalized with anti-C-terminal PTH antibody (2 nL;
175 μg/mL), using an inkjet printer (sciFLEXARRAYER
S3, Scienion AG), as described by Dittmer et.al. [12].
Functionalized optical parts were sealed with silica bags
and stored at 4°C.
Finally, the cartridge was assembled by connecting the
fluidic part and the optical part with double-sided tape that
was laser-cut to form a sample inlet, microfluidic channel, a
reaction chamber, and a vent. With a 100-μm tape and with
a 180-μm tape, a reaction chamber of 0.4 μL and a reaction
chamber of 0.5 μL were created, respectively. The
integrated PTH cartridges were sealed with silica bags and
stored at 4°C.
EDTA-plasma samples
EDTA-plasma unit used for the PTH-standard curve was
purchased from ProMedDx (MA, USA).
To prove the linear correlation between PTH concen-
trations covering the clinical relevant range (>70 pg/mL),
and the signals obtained with the magnotech ioPTH
assay, we used 20 EDTA-plasma samples with PTH
levels measured with a commercially available reference
PTH assay (Intact PTH, Roche Modular Analytics E170,
Roche Diagnostics, Germany). These samples from
anonymous patients screened for parathyroid disorders,
were left-over samples acquired from Labor Limbach
(Heidelberg, Germany).
To demonstrate that magnotech ioPTH assay is able to
detect a 50% decrease of PTH levels after resection of
the hyperfunctioning parathyroid tissue, blood samples
from two patients, undergoing parathyroid adenoma
surgery, were collected and tested on the magnotech
system. The EDTA-blood samples taken before surgery,
just before excision, and several time points after
resection, were centrifuged and, as a reference, PTH
levels were measured in a microtiter plate-based assay
(STAT-intraoperative intact-PTH assay, Future Diagnostics,
Wijchen, The Netherlands) [17].
ioPTH assay protocol
Either native PTH plasma samples or PTH-spiked plasma
were measured. For the latter, intact-PTH (Bachem,
Germany) was spiked to PTH-free EDTA plasma. PTH
levels were measured by injecting 10 μLo fs a m p l ei n t o
the inlet of the cartridge. After complete filling of the
reaction chamber, the actuation protocol was started. The
total assay time was 8 min. Unless otherwise stated, all
data points are from assays that were performed in
duplicates.
Results
PTH-dose response curve and precision
Using cartridges that were functionalized with anti-C-
terminal PTH antibodies on the detection spot, as well as
anti-N-terminal PTH antibodies on the magnetic particles,
and the magnotech technology, a PTH-dose response curve
was generated in EDTA-plasma. Various concentrations of
PTH were spiked in PTH-free EDTA plasma, and PTH
levels were measured with an 8-min assay protocol, using
0.5 μL of final sample volume (reaction chamber) (Fig. 3).
PTH-free EDTA plasma was measured in 12-fold and each
PTH-spiked plasma sample was measured in fivefold. At
the higher end of the PTH-dose response curve, a plateau in
signal (80 arbitrary units) was obtained for PTH concen-
trations ≥2,500 pg/mL. A linear correlation(r=0.997)
between concentrations and signals was found for PTH
concentrations, ranking from 0 to 1,500 pg/mL. Further-
more, PTH levels down to normal values (<70 pg/mL)
could significantly be measured. These findings implicate
that samples from patients with parathyroid adenoma who
have high PTH concentrations falling down to normal
values during surgery, could be accurately tested with the
magnotech ioPTH assay. The magnotech ioPTH assay is
aimed for a 20% CV (coefficient of variation) at the lower
limit of PTH normal values (10 pg/mL). The results
obtained in this study suggest that this objective can be
reached with a turnaround time of less than 10 min. In
addition, the CV in the linear range was calculated (n=28)
in EDTA-plasma with a PTH concentration of 500 pg/mL.
The CV was typically less than 10% (data not shown).
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Fig. 3 PTH dose–response curve measured with integrated PTH
cartridges. Using cartridges that contained a detection spot with
anti-C-terminal PTH antibodies and beads coated with anti-N-
terminal PTH antibodies, PTH-free EDTA plasma was measured in
12-fold and the PTH (1–84)-spiked plasma samples were measured
in fivefold. PTH levels were measured in a detection volume of
0.5 μL with an 8-min assay
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The linear correlation between PTH levels and signals
obtained with the magnotech ioPTH assay was further
demonstrated using 20 EDTA-plasma samples with a range
of native PTH concentration from 68 to 1,958 pg/mL
measured on a reference system. These samples were
measured with an 8-min protocol, using 0.4 μL of final
sample volume in the integrated PTH cartridge (Fig. 4). We
found a linear correlation (r=0.93) between PTH values
and signals obtained with magnotech ioPTH assay. Thus,
the magnotech ioPTH assay could be suitable for evaluation
of the 50% drop of PTH levels in plasma samples collected
during parathyroid adenoma surgery.
Fifty-percent drop of PTH after resection of parathyroid
gland
During two surgeries of parathyroid adenomas, EDTA-
plasma samples were collected before surgery (M1), just
before resection of the gland (M2), 5 min (M3), and 10 min
(M4) after resection. For patient #2, an additional sample at
20 min after resection (M5) was taken. PTH levels in these
samples were measured with the STAT-intraoperative
intact-PTH assay (Future Diagnostics) on site (Fig. 5a and
c). In both patients, the PTH levels before surgery were
dramatically higher than normal PTH levels (patient #1:
270 pg/mL; patient #2: 900 pg/mL). After a freeze-thaw
step, PTH levels in these samples were measured with an 8-
min protocol, using 0.4 μL of final sample volume
(reaction chamber) with the magnotech ioPTH assay
(Fig. 5b and d). For both patients, the PTH level in sample
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Fig. 4 Correlation on a limited number of native PTH samples.
Native PTH EDTA-plasma samples (n=20) with PTH concentrations
measured on the Roche Modular system were evaluated on the Philips
biosensor. The signal (arbitrary units) induced by these samples were
measured in cartridges that contained a detection spot with anti-C-
terminal PTH antibodies and beads coated with anti-N-terminal PTH
antibodies, using 0.4 μL detection volume and an 8-min assay
protocol
Fig. 5 Fifty-percentdropofPTH
levels10minafterresectionofthe
parathyroid adenoma. Various
EDTA-plasma samples were
collected during two surgeries of
parathyroid adenomas; samples
before surgery (M1), just before
resection (M2), 5 min (M3),
10 min (M4) ,a n d2 0m i n( M5)
after resection. These samples
were measured with the STAT-
intraoperative intact-PTH assay
on site (a and c) and, after a
freeze-thaw step, the signal
(arbitrary units) induced by these
samples were measured in
cartridges that contained a detec-
tion spot with anti-C-terminal
PTH antibodies and anti-N-
terminal PTH antibody-coated
beads, using 0.4 μLd e t e c t i o n
volume and an 8-min assay
protocol. The PTH levels in
sample M2 were used to
normalize the signal obtained
with the magnotech ioPTH assay
to 100% (b and d)
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integrated PTH cartridge to 100% and, next, a clear 50%
reduction of PTH concentration was found in the sample
that was collected 10 min after resection (sample M4).
Discussion
In this paper, we report a number of experiments that we
performed to illustrate the potential of the ioPTH assay on
the Philips handheld magnotech system. The work was
performed in a research setting that imposed a number of
limitations. The disposable cartridges were assembled in a
highly manual process, which likely introduced some
additional variations to the test results. Furthermore, the
experiments were performed on a very limited number of
native samples, which does not allow for a detailed
statistical analysis. Finally, the measurements with the
magnotech ioPTH assay presented in this study, were
performed with plasma as a sample matrix, where whole
blood will be required in the final application for optimal
ease-of-use; the next step will be to investigate how a
plasma separation membrane can be added to the dispos-
able cartridge, which would enable a measurement using
whole blood samples. This will remove the centrifugation
step currently in use to obtain the plasma, replacing it with
a step which is integrated in the cartridge and significantly
faster (<1 min). Despite these limitations, the preliminary
results we report provide an important step towards a
clinically usable POC ioPTH assay on magnotech system.
The PTH-dose response curve illustrates a linear correla-
tion between concentrations of PTH up to 1,500 pg/mL and
signals obtained with the magnotech ioPTH assay. As a
consequence, a 50% reduction of signal, expected after
resection of the hyperfunctioning parathyroid gland, could
be determined with the magnotech ioPTH assay. The experi-
mentswereperformed,usingintegratedcartridgesthatcontain
all reagents in a dry form, which proves that it is possible to
achieve good sensitivity in very short assay times. The error
barswerealreadyquitesmall,andtheseareexpectedtofurther
improve, once the disposable cartridges are manufactured in a
more automated fashion.
The comparative study shows that the results obtained
with the magnotech ioPTH assay correlate well with the
reference system. The observed scatter is likely due to the
combined effect of the characteristics of the individual
samples, the relatively low number of repeats, and the
aforementioned highly manual manufacturing method of
the cartridge. Despite all these, a very good correlation (r=
0.93) was already obtained in this early phase, which
should be considered as very encouraging.
The most convincing argument is formed by the measure-
ments that were carried out on samples from two patients
during surgery. The drop in PTH levels after removal of the
diseased gland is clearly visible, and could be used to provide
a surgeon with the immediate feedback that the operation has
beensuccessful.The goodcorrelation between the magnotech
ioPTH assay and the STATassay (Future Diagnostics) used as
a reference method, again, looks promising.
Based on our preliminary results with an in-house
magnotech ioPTH assay, we are confident that the next
commercially available magnotech ioPTH assay could
meet the requirements for ioPTH testing in the operating
theater. Further studies are necessary, including analyti-
cal, clinical, and health economics studies, to validate the
magnotech ioPTH assay as a reliable and cost-effective
solution to measure intraoperative PTH in patients,
undergoing parathyroidectomy.
Conclusion
We have developed a POC assay for ioPTH testing based
on Philips' magnotech handheld system. The PTH-dose
response curve shows that the clinically relevant concen-
trations of PTH can be accurately detected with a
turnaround time of less than 10 min. PTH measurements
with the magnotech ioPTH system on native plasma samples
are well correlated with the values obtained on a reference
system. Finally, and most relevantly, measurements per-
formed on samples from patients undergoing parathyroidec-
tomy show that a 50% drop in PTH concentration could be
clearly detected after the gland was removed. These results
illustrate the potential of the next magnotech ioPTH assay to
be a viable and easy-to-use solution to perform ioPTH
measurements in the operating theater.
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